Eli Lilly and Company (LLY) to Release Quarterly Earnings on Tuesday

Eli Lilly and Company (NYSE:LLY) is scheduled to be announcing its earnings results before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of $2.61 per share for the quarter. Eli Lilly and Company has set its FY 2024 guidance at 12.200-12.700 EPS and its FY24 guidance at $12.20-12.70 EPS.Persons that wish to register for the company’s earnings conference call can do so using this link.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same period last year, the business earned $2.09 earnings per share. The business’s quarterly revenue was up 28.1% on a year-over-year basis. On average, analysts expect Eli Lilly and Company to post $13 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Eli Lilly and Company Stock Up 0.7 %

Shares of NYSE LLY opened at $731.32 on Tuesday. Eli Lilly and Company has a one year low of $370.68 and a one year high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The firm’s 50 day simple moving average is $763.83 and its two-hundred day simple moving average is $662.78. The stock has a market capitalization of $694.87 billion, a P/E ratio of 126.09, a PEG ratio of 1.58 and a beta of 0.34.

Insider Transactions at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the completion of the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on LLY. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $775.00 to $850.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Barclays raised their price objective on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research report on Wednesday, February 7th. BMO Capital Markets raised their price objective on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a research report on Wednesday, February 7th. Truist Financial reissued a “buy” rating and set a $850.00 price objective on shares of Eli Lilly and Company in a research report on Friday, March 22nd. Finally, The Goldman Sachs Group raised their price objective on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Three investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.